Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.

Abstract

BACKGROUND:

Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop novel therapies to potentiate the anti-tumor effect and reduce the toxicity of oxaliplatin. In our previous study, we demonstrated that ethaselen (BBSKE), an inhibitor of thioredoxin reductase, effectively inhibited the growth of gastric cancer cells and promoted apoptosis in vitro. In the present study, we investigated whether BBSKE can potentiate the anti-tumor effect of oxaliplatin in gastric cancer in vivo and vitro.

METHODS:

Cellular apoptosis and ROS levels were analyzed by flow cytometry. Thioredoxin reductase 1 (TrxR1) activity in gastric cancer cells, organoid and tumor tissues was determined by using the endpoint insulin reduction assay. Western blot was used to analyze the expressions of the indicated proteins. Nude mice xenograft models were used to test the effects of BBSKE and oxaliplatin combinations on gastric cancer cell growth in vivo. In addition, we also used the combined treatment of BBSKE and oxaliplatin in three cases of gastric cancer Patient-Derived organoid (GC-PDO) to detect the anti-tumor effect.

RESULTS:

We found that BBSKE significantly enhanced oxaliplatin-induced growth inhibition in gastric cancer cells by inhibiting TrxR1 activity. Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells. In vivo, we also found that BBSKE synergized with oxaliplatin to suppress the gastric cancer tumor growth in xenograft nude mice model, accompanied by the reduced TrxR1 activity. Remarkably, we found that BBSKE attenuated body weight loss evoked by oxaliplatin treatment. We also used three cases of GC-PDO and found that the combined treatment of BBSKE and oxaliplatin dramatically inhibited the growth and viability of GC-PDO with increased ROS level, decreased TrxR1 activity and enhanced apoptosis.

CONCLUSIONS:

This study elucidates the underlying mechanisms of synergistic effect of BBSKE and oxaliplatin, and suggests that the combined treatment has potential value in gastric cancer therapy.

• Authors: Haiyong Zhang, Jing Wu, Jinqiu Yuan, Huafu Li, Yawei Zhang, Wang Wu, Wei Chen, Chunming Wang, Sijun Meng, Songyao Chen, Mingyu Huo, Yulong He, Changhua Zhang
• Journal: Journal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 40 Issue 1 Pg. 260 (08 19 2021) ISSN: 1756-9966 [Electronic] England
• PMID: 34412665 (Publication Type: Journal Article, Retracted Publication)
• Copyright: © 2021. The Author(s).

Chemical References

• (1,2-bis(1,2-benzisoselenazolone-3(2H)-ketone))ethane
• Bridged Bicyclo Compounds, Heterocyclic
• Organoselenium Compounds
• Reactive Oxygen Species
• Oxaliplatin
• TXNRD1 protein, human
• Thioredoxin Reductase 1

Topics

• Animals
• Apoptosis (drug effects)
• Bridged Bicyclo Compounds, Heterocyclic (pharmacology)
• Cell Line, Tumor
• Disease Models, Animal
• Drug Synergism
• Enzyme Activation
• Humans
• MAP Kinase Signaling System
• Male
• Mice
• Mice, Nude
• Organoids
• Organoselenium Compounds (pharmacology)
• Oxaliplatin (pharmacology)
• Reactive Oxygen Species (metabolism)
• Stomach Neoplasms (etiology, metabolism, pathology)
• Thioredoxin Reductase 1 (antagonists & inhibitors)
• Xenograft Model Antitumor Assays